Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Q3 2025 value amounting to $25.3 million.

  • Amphastar Pharmaceuticals' Change in Accured Expenses rose 279.94% to $25.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.2 million, marking a year-over-year decrease of 3077.0%. This contributed to the annual value of $63.6 million for FY2024, which is 38019.19% up from last year.
  • Amphastar Pharmaceuticals' Change in Accured Expenses amounted to $25.3 million in Q3 2025, which was up 279.94% from -$4.9 million recorded in Q2 2025.
  • Over the past 5 years, Amphastar Pharmaceuticals' Change in Accured Expenses peaked at $25.3 million during Q3 2025, and registered a low of -$14.7 million during Q3 2021.
  • For the 5-year period, Amphastar Pharmaceuticals' Change in Accured Expenses averaged around $6.2 million, with its median value being $3.7 million (2022).
  • In the last 5 years, Amphastar Pharmaceuticals' Change in Accured Expenses crashed by 116226.77% in 2022 and then skyrocketed by 280337.84% in 2023.
  • Over the past 5 years, Amphastar Pharmaceuticals' Change in Accured Expenses (Quarter) stood at -$1.1 million in 2021, then crashed by 1162.27% to -$13.6 million in 2022, then surged by 75.06% to -$3.4 million in 2023, then surged by 162.34% to $2.1 million in 2024, then soared by 1099.72% to $25.3 million in 2025.
  • Its last three reported values are $25.3 million in Q3 2025, -$4.9 million for Q2 2025, and $17.6 million during Q1 2025.